

Supplementary Information

Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection

Abenaya Muralidharan^{1,3}, Marsha Russell¹, Louise Larocque¹, Caroline Gravel¹, Changgui Li², Wangxue Chen⁴, Terry Cyr¹, Jessie R. Lavoie¹, Aaron Farnsworth¹, Michael Rosu-Myles^{1,3}, Lisheng Wang³, Xuguang Li^{1,3,*}

¹Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada.

²National Institute for Food and Drug Control and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China


³Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada

⁴Human Therapeutics Portfolio, National Research Council of Canada, Ottawa, ON, Canada


*Corresponding author

Supplementary Table 1: Primers used for cloning and sequencing of Ad-SF and Ad-SF40L constructs.


Name	Forward Primer (5' – 3')	Reverse Primer (5' – 3')
Primers for Cloning:		
Ad-SF40L	CACCGCCGCCACCATGCT	TCACAATTTCAACAAGCCAAA
Ad-SF	CACCGCCGCCACCATGCT	TCAATTGCTAAAGGCAATATTATTAATGCCGCTC
Primers for sequencing:		
SF40L-1F	CGCCGCCACCATGCTGCT	
SF40L-2F	AAAGGTAAAGCTCATCAAGCAGGAGC	
SF40L-3F	CAACAAGGCAGTAGTTTCCC	
SF40L-4F	GAGCAACAACGTCCAGATCGTGA	
SF40L-5F	TCTGCCTTCTGAAGTCAACTTGTGCA	
SF40L-6F	TATTAATTTCTATGACCCCCTGG	
SF40L-7F	TGGCTATATACCTGAGGCCCCCA	
SF40L-8F	CAAAGGCGAGGGGTCTCTGT	
SF40L-9F	GGTGACATTTTGCTCAAATCGCG	





Supplementary Fig. 1: Representative image of H&E and PAS stained lungs of mice post-challenge. BALB/c mice were intranasally immunized twice with control vaccines, Ad-Empty or Ad-SNP40L, to determine the antigen specificity of the observed protection. Lungs were H&E and PAS stained 4 days post challenge for perivascular leukocyte infiltrate and mucus scoring, respectively. Representative images at 40x magnification are shown.



Supplementary Fig. 2: TEM gating strategy. Splenocytes were isolated from immunized BALB/c mice before or after challenge and stained for flow cytometry analysis. A FSC/SSC plot was done to gate for lymphocytes (A). Singlets were selected from the lymphocytes (B) and further gated for viable cells (C). The viable cells were then gated for CD3+CD8a+ (D). Next, the CD3+CD8a+ cells were analyzed for CD44+CD62L- (E), which were finally gated for CCR7- population (F). This CD3+ CD8a+ CD44+ CD62L- CCR7- is denoted as effector/effector memory CD8 T cells or TEM.



Supplementary Fig. 3: Increase in CD8 T cell effector phenotype and function following challenge is unique to Ad-SF40L immunization. (A) Schematic diagram of the animal study with BALB/c mice. Mice were necropsied for tissue collection before or after challenge. (B) Flow cytometry was used to determine the TEM population (CD3⁺ CD8⁺ CD44⁺ CD62L⁻ CCR7⁻) in the spleen. (C) Intracellular cytokine staining was done following 4-hour ex-vivo stimulation with F85-93 peptide to analyze the number of CD8⁺ TNF- α ⁺ cells in the spleen using flow cytometry. Data shown is mean \pm SEM; n = 4 per group representative of 2 separate experiments; *p < 0.05, **p < 0.01 (one-way ANOVA with Bonferroni posttest).



Supplementary Fig. 4: CD40L does not enhance CD4 T cell-induced protection. (A) Schematic diagram of the animal study timeline. Adoptive CD4 T cell transfer was done from immunized and challenged donor mice into naïve recipient mice. CD4 T cells were isolated from spleens of donor mice using a magnetic bead kit and checked for purity prior to transfer. (B) Four days post-challenge, lungs from the recipient mice were collected for viral titer determination using plaque assay. There were no significant differences between Ad-SF and Ad-SF40L group. Data shown is mean ± SEM; n = 4 per group; *p < 0.05, **p < 0.01 (one-way ANOVA with Bonferroni posttest).